Sign up
Tech Capital

Simulations Plus’ software can fast-track the regulatory process for new drugs

Simulations Plus Inc (NASDAQ:SLP) President, Lancaster Division, John DiBella tells Proactive Investors about how their modeling and simulation software can bring new drugs to market faster.

The software company provides simulation software to pharmaceutical and biotech companies, allowing the developers to predict endpoints.

“We can really help companies identify sooner potential loser compounds so that they’re not wasting resources at that discovery going into pre-clinical stage,” said DiBella.

With regulatory permission, the companies can use those results to waive certain clinical studies, saving the company potentially millions of dollars in trial costs and speeding up the regulatory process.

Going forward, the software may branch out into other markets such as healthcare or aerospace.

 

View full SLP profile View Profile
View All

© tech Capital 2018

Tech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed tech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Tech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Technology market.